Cancer Care

 

 
The High-Dose Aldesleukin (IL-2) `Select` Trial: A Prospective Tissue Collection Protocol to Investigate Predictove Models of Response to High Dose IL-2 Treatment in Patients with Advanced Melanoma
Principal Investigator (?)
Study Number
W1043
Summary
The purpose of this study is to determine which participants with melanoma have a better
response to IL-2 and to identify markers that may predict response to IL-2 by collecting
participant information (for example; cancer diagnosis and history, prior treatments for
cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after
treatment.
Phase (?)
N/A
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.